WO2010058419A1 - Tumor necrosis factor alpha inhibiting peptides and uses thereof - Google Patents

Tumor necrosis factor alpha inhibiting peptides and uses thereof Download PDF

Info

Publication number
WO2010058419A1
WO2010058419A1 PCT/IN2009/000626 IN2009000626W WO2010058419A1 WO 2010058419 A1 WO2010058419 A1 WO 2010058419A1 IN 2009000626 W IN2009000626 W IN 2009000626W WO 2010058419 A1 WO2010058419 A1 WO 2010058419A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
gin
group
aminoacids
ser
Prior art date
Application number
PCT/IN2009/000626
Other languages
English (en)
French (fr)
Other versions
WO2010058419A4 (en
Inventor
Rajesh Jain
Virendra Kumar Vinayak
Shweta Dubey
Sudhanand Prasad
Vijay Goel
Rahul Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG2011036068A priority Critical patent/SG171348A1/en
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to EP09827268A priority patent/EP2362880A1/en
Priority to CA2744365A priority patent/CA2744365A1/en
Priority to AU2009318779A priority patent/AU2009318779A1/en
Priority to CN2009801545421A priority patent/CN102282163A/zh
Priority to JP2011537012A priority patent/JP2012509312A/ja
Priority to MA33940A priority patent/MA33084B1/fr
Priority to RU2011151260/02A priority patent/RU2011151260A/ru
Priority to US13/130,267 priority patent/US20120010158A1/en
Priority to MX2011005363A priority patent/MX2011005363A/es
Publication of WO2010058419A1 publication Critical patent/WO2010058419A1/en
Publication of WO2010058419A4 publication Critical patent/WO2010058419A4/en
Priority to IL213026A priority patent/IL213026A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to biologically active peptides and process for the preparation thereof.
  • the present invention further relates to Tumor Necrosis Factor-alpha (TNF- ⁇ or TNF-alpha) inhibiting peptides and proceMss for the preparation thereof.
  • the present invention further relates to a pharmaceutical composition comprising said peptide molecules and uses thereof in treating Tumor Necrosis Factor - alpha (TNF- ⁇ or TNF-alpha) mediated inflammatory disorder such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and sepsis etc.
  • Cytokines are a class of signaling proteins produced by activated immune cells i.e. B cells, T cells and monocytes and macrophages.
  • the cytokines include family of interleukins (IL-I through IL-23), Interferons (alpha, beta and gamma) and TNF- ⁇ and ⁇ (Janeway CA et al. 1999, Immunobiology, 4 th Ed. New York, Garland, 1999; Roitt I et al. 2002, Immunology 5 th ed. London, Mosby, 2002).
  • TNF-alpha was originally discovered as a molecule which caused hemorrhagic necrosis of mouse tumors (Carswell et al., 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3666).
  • TNF-alpha has now been established as a broadly active inflammatory mediator involved in diverse clinical conditions.
  • TNF-alpha is a 17 kD molecular weight protein produced by several cell types, particularly activated macrophages.
  • TNF-alpha is initially synthesized as a transmembrane protein arranged in stable trimers. This is subsequently cleaved by metalloprotease-TNF alpha converting enzyme (TACE) to form the homotrimeric soluble TNF (sTNF) which engages to its cognate receptors (TNFRI, p55 and TNFRII, p75), expressed ubiquitously.
  • TACE metalloprotease-TNF alpha converting enzyme
  • sTNF homotrimeric soluble TNF
  • TNFRI TNFRI, p55 and TNFRII, p75
  • the ubiquitous expression of TNF receptors along with cell specific effectors explains wide variety of TNF- ⁇ mediated cellular response, some of which are deleterious and life threatening. These receptors when shed from mononuclear cells, lower the TNF- ⁇ levels by mopping up and acting
  • TNF-alpha induces a wide variety of cellular responses, many of which result in deleterious consequences.
  • TNF-alpha induces cachexia which is a condition resulting from loss of fat and whole body protein depletion, accompanied by insufficient food intake due to anorexia. Cachexia is commonly seen in cancer patients, and it has also been observed in patients with acquired immunodeficiency syndrome (AIDS).
  • AIDS acquired immunodeficiency syndrome
  • injection of high doses of TNF-alpha in animals produces most of the symptoms of septic shock.
  • TNF-alpha has also been shown to play a role in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, psoriasis, psoriatic arthritis, hypersensitivity, immune complex diseases and graft versus host disease as well as transplantation rejection.
  • the involvement of TNF-alpha has even been implicated in malaria and lung fibrosis. Therefore it is of considerable interest and therapeutic benefit to target blocking of TNF-alpha production in disease conditions.
  • TNF-receptor fusion proteins have been introduced as TNF-antagonists in human patients (Peppel et al., 1991, J. Exp. Med. 174:1483; Williams et al., 1995, Immunol. 84:433; Baumgartner et al., 1996, Arthritis Rheumat. 39(Suppl.) S74).
  • United States Patent 6265535 relates to the cyclic peptides and peptide analogues designed from a binding loop of a TNF-receptor superfamily member which interfere with the binding interactions between TNF-alpha and TNF-receptor, exhibiting inhibitory activities in-vitro as well as in-vivo, to antagonize the undesirable biological activities of TNF in vivo.
  • This invention prefers cyclized peptides since loops and turns in play functionally important roles in protein-protein interactions.
  • cyclic peptides have been designed from three binding loops of TNF-R p55 which bind with TNF- ⁇ and inhibit the binding of TNF- ⁇ to its cellular receptors. Most preferred embodiments have atleast 7 amino acids and there is no suggestion that smaller linear peptides could be useful as TNF alpha inhibitors.
  • United States Patent 6344443 relates to a method for inhibiting TNF-alpha binding to TNF receptors and TNF- ⁇ function by administering an effective amount of an inhibitory peptide.
  • the patent relates to the peptides which bind to TNF receptors and interfere with the ability of TNF- ⁇ to bind to and activate cellular TNF- ⁇ receptors.
  • this invention relates to the use of peptides having 7 and 12 aminoacid residues for inhibiting TNF-alpha binding to TNF receptors and TNF function.
  • the '443 document aims at screening small peptides that could bind to TNF receptors. The smallest molecule that has been identified is 7 amino acid long sequence. There is no suggestion that further smaller peptides could be useful as TNF alpha inhibitors.
  • United States Patent 6143866 relates to a urine derived TNF inhibitor peptide.
  • the patent further relates to purified forms of TNF inhibitor which are active against TNF alpha.
  • the patent further relates to purified forms of TNF inhibitor which would be valuable as pharmaceutical preparations exhibiting activity against TNF. It further relates to 30 kDa protein and a 40 kDa protein which have been obtained in their purified forms.
  • the amino acid sequences disclosed for these proteins is not less than 15 amino acids long, hence there is no suggestion that further smaller peptides could be useful as TNF alpha inhibitors.
  • United States Patent 6048543 relates to the use of at least one amino acid selected from the group consisting of glycine, alanine and serine, or the physiologically acceptable salts thereof, in the preparation of a medicament or nutritional formulation for the diminution of tumor necrosis factor (TNF) levels in patients in whom said levels are elevated beyond those which mediate physiological homeostasis and local inflammation.
  • TNF tumor necrosis factor
  • the patent discloses that the diminution of TNF levels can be achieved by inhibition or diminution of, TNF production by macrophage-type cells or TNF release by macrophage type cells or binding of TNF by TNF receptors.
  • the patent relates to the use of only glycine, alanine and serine in the preparation of a medicament or nutritional formulation for diminution of TNF levels.
  • the patent does not disclose any use of combination of aminoacids or peptides containing combination of aminoacids.
  • United States Patent 6107273 relates to TNF- ⁇ antagonist compounds that comprise a molecular surface that is substantially similar to at least one molecular surface of human TNF- ⁇ selected from the group of molecular surfaces of human TNF- ⁇ .
  • the compounds of the invention have linking moiety attached at both the ends and a spacer moiety.
  • the compound of the invention discloses the TNF-alpha inhibiting peptides having 25 aminoacids along with a linking moiety and a spacer moiety.
  • the TNF- ⁇ antagonist compounds of the '273 patent binds to TNF p55 receptor and/or TNF p75 receptor and inhibit TNF- ⁇ mediated cytotoxicity.
  • the '273 patent does not suggest the smaller peptides without the spacer moieties.
  • the therapeutics currently available in this area has been designed to neutralize TNF- ⁇ by using soluble TNF receptors or monoclonal anti-TNF antibodies (Piguet et al. 1992, Immunology 77:510-514; Elliot et al. 1993, Arthritis Rheum. 36: 1681-90). These bind to circulating TNF- ⁇ thereby limiting latter' s accessibility to TNF-R on cell surface and subsequent activation of inflammatory pathways.
  • Infliximab (Remicade): a mouse human chimeric anti- human TNF-alpha monoclonal antibody
  • Humira a fully human anti TNF- alpha monoclonal antibody
  • Etanercept a dimeric fusion protein of soluble P75sTNF-RII fused to Fc portion of human IgG.
  • Peptidomimetic WP9QY showed therapeutic values and reduced the severity of experimental autoimmune encephalomyelitis (EAE) & Rheumatoid arthritis (RA) in mice.
  • EAE experimental autoimmune encephalomyelitis
  • RA Rheumatoid arthritis
  • its relatively poor solubility in physiological puffers is a limiting factor in its use as a potential human therapeutic (Takasaki et al. 1997, Nat. Biotechnol. Nov. 15(12):1266-70).
  • cyclization and aromatization of a peptide enhanced stability and bioavailability yet little or no effect on enhanced solubility or enhanced activity was noticed by Takasaki et al, 1997.
  • a biologically active peptide having the formula: X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • a TNF- ⁇ inhibiting peptide having the formula: X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • the present invention further relates to the use of biologically active peptides of the present invention for the treatment of TNF- ⁇ related disease conditions.
  • the present invention also relates to a pharmaceutical composition comprising biologically active peptides of the present invention.
  • Figure 1 shows Anti-TNF- ⁇ activity of the peptides employing L929 bioassay.
  • Numbers 1-10 on X-axis denotes the peptides of Sequence ID - 1 to 10.
  • Y axis denotes the Mean ⁇ SE percentage inhibition of TNF-alpha mediated cytotoxicity of three independent experiments, each run in duplicate.
  • '+ve' denotes positive control i.e. a known TNF-alpha inhibitory peptide i.e. Cyclic WSQYL (cy Trp-Ser-Gln-Tyr-Leu).
  • Figure 2 shows comparison of linear peptide of Sequence ID- 2 and Sequence ID-6; cyclic peptide of Sequence ID-9 and Sequence ID-10 and positive control i.e. Cyclic WSQYL (cy Trp-Ser-Gln-Tyr-Leu) peptide to inhibit TNF- ⁇ induced cytotoxicity. Results have been expressed as Mean ⁇ SE percentage inhibition of " TNF-alpha mediated cytotoxicity of three independent experiments, each run in triplicate.
  • Figure 3 shows comparison of inhibition of TNF-alpha mediated cytotoxicity by peptide of sequence ID-6 and Etanercept (Et). Results have been expressed as Mean ⁇ SE percentage inhibition of TNF-alpha mediated cytotoxicity of two independent experiments, each run in triplicate.
  • FIG 4 shows quantification of binding of peptides to TNF-alpha by Flow cytometry.
  • Fluorescence- Activated Cell Sorter (FACS) analysis of TNF-alpha binding to cellular receptors in presence of peptide with Sequence ID-2 and Sequence ID - 6 is presented in Fig 4a.
  • Y-axis denotes the Mean ⁇ SE percent cells positive for TNF-RI expression of three independent experiments.
  • Numbers 1 - 5 on the X axis in the bar diagram (Fig 4a) or in the flow cytometric histogram (Fig 4b) are as follows:
  • Figure 5 shows binding of peptide of Sequence ID - 6 to TNF-Rl on U937 cells: Fluorescence-Activated Cell Sorter (FACS) analysis of binding of peptide with Sequence ID-6 to TNF-Rl expressed on U937 cells is presented in Fig 5.
  • Y-axis denotes the Mean ⁇ SD percent cells positive for TNF-RI expression of two independent experiments. Numbers on the X-axis in the bar diagram or in the flow cytometry histogram overlay (Fig 5) represents following samples:
  • Figure 6 shows estimation of anti-collagen IgG levels from serum of vehicle
  • CFA control (PBS) and collagen immunized mice.
  • Figure 7 shows Mean of paw thickness values in right tarsal before treatment
  • Each group included 4-5 animals.
  • Values on Y axis represent Mean ⁇ SE of paw thickness in respective groups.
  • Animal groups are represented on the X axis by alphabets, namely,
  • A arthritic mice treated with 1.25 mg/kg of peptide with Sequence ID-6 at a schedule of three times in a week followed by once every week for three weeks
  • B arthritic mice treated with 2.5 mg/kg of peptide with Sequence ID-6 at a schedule of three times in a week followed by once every week for three weeks
  • E arthritic mice treated with 7.5 mg/kg of peptide with Sequence ID-6 at a schedule of one dose in first week followed by second dose after 3 weeks
  • F arthritic mice treated with PBS as control
  • Figure 8 shows Mean ⁇ SE of paw thickness values in left and right tarsal before treatment (Pre Tx) and after treatment (Post Tx) with peptide of sequence ID-6, peptide of Sequence ID-2 and Etanercept (Et).
  • PBS treated animals are considered as untreated animals and Control denotes the healthy male C57BL/6 mice, p values have been calculated before and after treatment. ** indicates p value ⁇ 0.01, * indicates p ⁇ 0.05,
  • Figure 8 (b) shows comparative anticollagen IgGl/IgG2a ratios after therapy in animals treated with peptide of Sequence ID-6, peptide of Sequence ID-2 and Etanercept (Et).
  • PBS treated animals are considered as untreated animals and Control denotes the healthy male C57BL/6 mice, p values have been calculated before and after treatment. ** indicates p value ⁇ 0.01, * indicates p ⁇ 0.05.
  • Figure 9 shows mean of paw thickness values in right tarsal and right joint before (Pre Tx) and after treatment (Post Tx) with peptide sequence ID-6 and Etanercept (Et). PBS treated animals are considered as untreated animals. Each group included 3 animals.
  • Figure 9 (b) shows comparative clinical score before treatment (Pre Tx) and after treatment (Post Tx) with peptide sequence ID-6 and Etanercept (Et) in rat model of adjuvant induced arthritis.
  • PBS treated animals are considered as untreated animals.
  • Each group included 3 animals, p values have been calculated before and after treatment. ** indicates p value ⁇ 0.01, * indicates p ⁇ 0.05.
  • Figure 10 shows representative photographs of paw and joint swelling in arthritic rats before and after treatment with sequence ID-6, Etanercept or PBS as negative control.
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • the present invention also relates to a TNF- ⁇ inhibiting peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 , X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • the present invention further relates to biologically active peptides that act as TNF-alpha inhibitors.
  • the biologically active peptides according to the present invention may act by different mechanisms like for example, but not limited to, following:
  • the peptides of the present invention can bind to the TNF-alpha to form a complex, resulting in prevention of binding of TNF-alpha to
  • TNF-Rl receptors TNF-Rl receptors.
  • the peptides of the present invention can directly bind to the TNF-Rl receptors and can prevent TNF-alpha from binding to TNF-Rl receptors.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula:
  • X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • the present invention also relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula: X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids.
  • the present invention relates to a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids, and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to a TNF- ⁇ inhibiting peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids,_and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids, and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xj, X 2 are each independently 0-2 aminoacids; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising hydrophilic aminoacids, hydrophobic aminoacids and cysteine like aminoacids, and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids selected from the group comprising Tip, Ser, GIn, Asn, Tyr and Leu; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising Trp, Ser, GIn, Asn, Tyr and Leu, and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to a TNF- ⁇ inhibiting peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 are each independently 0-2 aminoacids selected from the group comprising Trp, Ser, GIn, Asn, Tyr and Leu; X 3 is a single aminoacid residue; and aminoacids can be selected from the group comprising Tip, Ser, GIn, Asn, Tyr and Leu, and wherein Xi, X 2 and X 3 when taken together are not less than 2 aminoacids.
  • the present invention relates to a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 and X 3 are each independently a single aminoacid residue selected from the group comprising Tip, Ser, GIn, Asn, Tyr and Leu.
  • the present invention relates to a TNF- ⁇ inhibiting peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi, X 2 and X 3 are each independently a single aminoacid residue selected from the group comprising Tip, Ser, GIn, Asn, Tyr and Leu.
  • the present invention relates to a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is 0-2 aminoacids selected from the group comprising Tip, Ser, GIn; X 2 is 0-2 aminoacids selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is an aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention relates to a TNF- ⁇ inhibiting peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is 0-2 aminoacids selected from the group comprising Tip, Ser, GIn; X 2 is 0-2 aminoacids selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is an aminoacid residue selected from the group comprising GIn, Leu, and Tyr, and wherein Xl, X2 and X3 when taken together are not less than 2 aminoacids.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula: X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X) is 0-2 aminoacids selected from the group comprising Trp, Ser, GIn; X 2 is 0-2 aminoacids selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is an aminoacid residue selected from the group comprising GIn, Leu, and Tyr, and wherein Xl, X2 and X3 when taken together are not less than 2 aminoacids; and a pharmaceutically acceptable carrier.
  • the present invention further relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 is 0-2 aminoacids selected from the group comprising Trp, Ser, GIn; X 2 is 0-2 aminoacids selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is an aminoacid residue selected from the group comprising GIn, Leu, and Tyr, and wherein Xl, X2 and X3 when taken together are not less than 2 aminoacids.
  • a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 is 0-2 aminoacids selected from the group comprising Trp, Ser, GIn; X 2 is 0-2 aminoacids selected from the group comprising Ser, GIn, Asn, and Tyr; and
  • the present invention further relates to a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is Trp then X 2 is Ser or GIn.
  • the present invention further relates to a TNF- ⁇ inhibiting peptide having the formula:
  • X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula:
  • Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn
  • X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr
  • X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is Trp then X 2 is Ser or GIn.
  • the present invention further relates to a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is Ser then X 2 is Asn or GIn.
  • the present invention further relates to a TNF- ⁇ inhibiting peptide having the formula: X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is Ser then X 2 is Asn or GIn.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula:
  • X 1 -X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Tip, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to a TNF- ⁇ inhibiting peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active peptide having the formula:
  • Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein Xi is aminoacid residue selected from the group comprising Tip, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is GIn then X 2 is Asn or Tyr, and a pharmaceutically acceptable carrier.
  • the present invention further relates to the method of treating TNF- ⁇ related disease conditions comprising administering a biologically active peptide having the formula: Xi-X 2 -X 3 or pharmaceutically acceptable salts and derivatives thereof, wherein X 1 is aminoacid residue selected from the group comprising Trp, Ser, GIn; X 2 is aminoacid residue selected from the group comprising Ser, GIn, Asn, and Tyr; and X 3 is aminoacid residue selected from the group comprising GIn, Leu, and Tyr; with the proviso that if Xi is GIn then X 2 is Asn or Tyr
  • peptide refers to polymers formed by naturally occurring amino acid subunits joined by peptide bonds.
  • amino acid may also refer to moieties which have portions similar to naturally occurring peptides but which have non-naturally occurring portions. Thus, peptides may have altered amino acids or linkages.
  • biologically active peptide refers to the peptide which shows any kind/amount of pharmacological or biological effect when administered to mammals.
  • aminoacid/aminoacid residues used above may be genetically encoded L-aminoacids, naturally occurring non-genetically encoded aminoacids, synthetic L-aminoacids or D-enantiomer/s of all of the above or pharmaceutically acceptable salts/derivatives thereof.
  • amino acid notations used herein for the twenty genetically encoded L-amino acids and common non-encoded amino acids are conventional and are as follows: Table - 1
  • the peptides that are encompassed within the scope of the invention are partially defined in terms of amino acid residues of designated classes.
  • the amino acids may be generally categorized into three main classes: hydrophilic amino acids, hydrophobic amino acids and Cysteine-like amino acids, depending primarily on the characteristics of the amino acid side chain. These main classes may be further divided into subclasses.
  • Hydrophilic amino acids include amino acids having acidic, basic or polar side chains and hydrophobic amino acids include amino acids having aromatic or apolar side chains.
  • Apolar amino acids may be further subdivided to include, among others, aliphatic amino acids.
  • Hydrophobic Amino Acid refers to an amino acid having a side chain that is uncharged at physiological pH and that is repelled by aqueous solution.
  • genetically encoded hydrophobic amino acids include He, Leu and VaI.
  • non-genetically encoded hydrophobic amino acids include t-BuA.
  • Aromatic Amino Acid refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated .pi.-electron system (aromatic group).
  • aromatic group may be further substituted with substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfanyl, nitro and amino groups, as well as others.
  • substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfanyl, nitro and amino groups, as well as others.
  • Examples of genetically encoded aromatic amino acids include phenylalanine, tyrosine and tryptophan.
  • Non-genetically encoded aromatic amino acids include phenylglycine, 2-naphthylalanine, .beta.-2-thienylalanine, 1,2, 3, 4- tetrahydroisoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2- fluorophenylalanine, 3-fluorophenylalanine and 4-fluorophenylalanine.
  • Apolar Amino Acid refers to a hydrophobic amino acid having a side chain that is generally uncharged at physiological pH and that is not polar.
  • Examples of genetically encoded apolar amino acids include glycine, proline and methionine.
  • Examples of non-encoded apolar amino acids include Cha.
  • Aliphatic Amino Acid refers to an apolar amino acid having a saturated or unsaturated straight chain, branched or cyclic hydrocarbon side chain.
  • genetically encoded aliphatic amino acids include Ala, Leu, VaI and lie.
  • non-encoded aliphatic amino acids include NIe.
  • Hydrophilic Amino Acid refers to an amino acid having a side chain that is attracted by aqueous solution.
  • examples of genetically encoded hydrophilic amino acids include Ser and Ly s.
  • examples of non-encoded hydrophilic amino acids include Cit and hCys.
  • Acidic Amino Acid refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Examples of genetically encoded acidic amino acids include aspartic acid (aspartate) and glutamic acid (glutamate).
  • Basic Amino Acid refers to a hydrophilic amino acid having a side chain pK value of greater than 7.
  • Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion.
  • genetically encoded basic amino acids include arginine, lysine and histidine.
  • non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2,3-diaminopropionic acid, 2,4- diaminobutyric acid and homoarginine.
  • Poly Amino Acid refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has a bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
  • genetically encoded polar amino acids include asparagine and glutamine.
  • non-genetically encoded polar amino acids include citrulline, N-acetyl lysine and methionine sulfoxide.
  • cyste-Like Amino Acid refers to an amino acid having a side chain capable of forming a covalent linkage with a side chain of another amino acid residue, such as a disulfide linkage.
  • cysteine-like amino acids generally have a side chain containing at least one thiol (SH) group.
  • examples of genetically encoded cysteine-like amino acids include cysteine.
  • examples of non-genetically encoded cysteine-like amino acids include homocysteine and penicillamine.
  • cysteine has both an aromatic ring and a polar hydroxyl group.
  • cysteine has dual properties and can be included in both the aromatic and polar categories.
  • cysteine in addition to being able to form disulfide linkages, cysteine also has apolar character.
  • cysteine can be used to confer hydrophobicity to a peptide.
  • Certain commonly encountered amino acids which are not genetically encoded of which the peptides and peptide analogues of the invention may be composed include, but are not limited to, .beta.-alanine (b-Ala) and other omega-amino acids such as 3-aminopropionic acid (Dap), 2,3- diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth; .alpha.
  • - aminoisobutyric acid (Aib); .epsilon.-aminohexanoic acid -(Aha); .delta.- aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGIy); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N- methylisoleucine (MeIIe); phenylglycine (Phg); cyclohexylalanine (Cha); norleucine (NIe); 2-naphthylalanine (2-Nal); 4-chlorophenylalanine (Phe(4- Cl)); 2-fluorophenylalanine (Phe(2-F)); 3-fluorophenylalanine (Phe(3-F)); 4- fluorophenylalanine (Phe(4-F)); penicill
  • biologically active peptides include, but not limited to, the following Sequences:
  • Sequence ID -5 Ser-Gln-Leu (SQL)
  • Sequence ID-- 6 Ser ⁇ Asn-Tyr (SNY)
  • Sequence ID -9 cyclic Trp-Ser-Leu CY (cy WSL)
  • Sequence ID-IO cyclic Ser-Asn-Tyr CY (cy SNY) Sequence ID- 11 : Trp-Gln-Gln (WQQ)
  • Sequence ID- 14 Trp-Gln-Leu (WQL) Sequence ID-15: Trp-Asn-Leu (WNL)
  • Sequence ID-18 Tip-Asn-Tyr (WNY) Sequence ID- 19: Trp ⁇ Tyr ⁇ Tyr (WYY)
  • Sequence ID-20 Ser-Ser-Gln (SSQ)
  • Sequence ID-21 Ser-Gln-Gln (SQQ)
  • Sequence ID-22 Ser-Asn ⁇ Gln (SNQ)
  • Sequence ID-23 Ser ⁇ Ser ⁇ Leu (SSL) Sequence ID-24: Ser-Asn-Leu (SNL)
  • Sequence ID-26 Ser-Ser-Tyr (SSY)
  • Sequence ID-28 Ser ⁇ Tyr ⁇ Tyr (SYY) Sequence ID-29: Gln-Ser-Gln (QSQ)
  • Sequence ID-33 Gln-Ser ⁇ Leu (QSL)
  • Sequence ID-34 Gln ⁇ Gln-Leu (QQL)
  • biologically active peptides include, but not limited to,
  • Ser ⁇ Asn ⁇ Tyr SNY
  • Sequence ID - 6 and Trp ⁇ Ser--Leu WSL
  • the peptides of the present invention can be linear or cyclic, preferably the peptides are linear.
  • a sequence of peptide with known TNF-alpha inhibitor activity Cyclic WSQYL (cy Trp-Ser-Gln-Tyr-Leu CY) was used as positive control in evaluating TNF- ⁇ antagonistic activity in in-vitro study.
  • the symbol “— " between amino acid residues X n generally designates a backbone interlinkage.
  • the symbol “—” usually designates an amide linkage (— C (O)-NH).
  • one or more amide linkages may optionally be replaced with a linkage other than amide, preferably a substituted amide or an isostere of an amide linkage.
  • TNF-alpha or TNF- ⁇ means the same i.e. TNF-alpha or Tumor necrosis factor - alpha.
  • the peptides of the present invention can be synthesized by any method known in the art.
  • the novel peptides of the present invention were synthesized by solid phase techniques using Fmoc Strategy on automatic peptide synthesizer (Applied Biosystems 433 A Peptide Synthesizer) at 1.00 mmol scale.
  • the peptides were assembled from C-terminus to N-terminus.
  • Peptides were synthesized using Wang Resin.
  • the resin employed for synthesis was Wang resin (100-200 mesh) procured from Novabiochem (Substitution 1.2 mmol/g resin).
  • the chemical moieties were used to protect reactive side chains of the peptides during synthesis procedure.
  • the N-terminal amino group was protected by 9- fluorenylmethoxycarbonyl (Fmoc) group.
  • the side chain of Leucine was used unprotected.
  • the side chain of Tryptophan was tert-Butoxycarbonyl (Boc) protected.
  • the side chain of Asparagine and glutamine was trityl (tit) protected.
  • Serine and tyrosine were used with t-Butyl (tBu) protection.
  • Cysteine was S-acetamidomethyl (Acm) protected.
  • the first amino acid was loaded on the Wang resin using 4-dimethyaminopyridine (DMAP) and Diisopropylcarbodiimide (DIC) and followed by capping using acetic anhydride.
  • the activating reagents used for coupling amino acids to the resin include 2-(lHbenzotriazol-l-yl)-l, 1, 3, 3-tetramethyluronium hexafluorophosphate/1-hydroxybenzotriazole (HBTU/HOBt) and diisopropylethylamine (DIEA).
  • the coupling reaction was carried out in NMP. After the assembly of the peptide chain was completed the peptide-resin was washed with methanol and dried.
  • the peptide was cleaved from resin by treatment with a cleavage mixture consisting of trifluoroacetic acid, crystalline phenol, thioanisol, ethanedithiol and de-ionized water for 2-3 hrs at room temperature.
  • the crude peptide was obtained by precipitation with cold dry ether. The precipitate was then filtered and dissolved in water and lyophilized in Vertis freeze dryer.
  • the resulting crude peptide was purified by preparative HPLC using a Phenomenex C18 (250 X 22.1) reverse phase column using a gradient of 0.1% TFA in Acetonitrile and water.
  • the cyclic forms of the peptides were cyclized on resin using iodine in dimethylformamide (DMF).
  • DMF dimethylformamide
  • the resin was treated with six fold molar excess of Iodine in DMF with mild shaking on automated shaker. The progress of the reaction was monitored by HPLC. After completion of the reaction the resin was quenched with 0.4 M Ascorbic acid in DMF. The resin was then washed with DMF and methanol and dried in vacuo for a few minutes. The cyclized peptide was finally cleaved from the resin and analyzed by RP-HPLC. The crude peptide was purified by prep HPLC and characterized by Electrospray mass spectroscopy.
  • the peptides of the invention have been purified by art- known techniques such as high performance liquid chromatography (HPLC), ion exchange chromatography, gel electrophoresis, affinity chromatography and the like; preferably chromatographic technique. More preferably, the peptides may be purified on a semi-preparative Shimatzu HPLC system using a RP C- 18 column. The actual conditions used depend on factors like net charge, hydrophobicity, hydrophilicity etc.
  • the peptides of the present invention may be analysed by art-known techniques such as mass spectrometry, SDS-PAGE, isoelectric focusing, 2D- eletrophoresis, chromatography- gel Filtration (separation on basis of size), ion exchange (separation on basis of charge), sequencing, protease specificity, HPLC, X-Ray crystallography etc. More preferably the peptides of the present invention have been analyzed by mass spectrometry.
  • the purity of peptides can be determined by any method known in the art.
  • the purity of the peptides was determined by reverse phase HPLC.
  • the peptides of the present invention were analyzed for the purity.
  • the peptides of the present invention are obtained with higher purity.
  • Peptides of the present invention are soluble in water, physiological buffer such as acetate buffer, phosphate buffer or PBS containing DMSO.
  • the TNF-alpha inhibitors according to the invention are useful for treating a pathology or condition associated with levels of TNF-alpha, in excess of the levels present in a normal healthy subject.
  • pathologies include, but are not limited to: acute and chronic immune and autoimmune pathologies, such as rheumatoid arthritis , systemic lupus erythematosus, psoriasis and; sepsis syndrome, including cachexia; circulatory collapse and shock resulting from acute or chronic bacterial infection; acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections; Crohn's disease, and malignant pathologies involving TNF-alpha-secreting tumors.
  • compositions comprising the peptides of the present invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active peptides or peptide analogues into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • Suitable pharmaceutical carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
  • compositions of the present invention may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal.
  • the peptides of the present invention can be administered by any route of administration known in the art.
  • the various routes of administration includes, but not limited to, topical, parenteral, transmucosal, oral, buccal, rectal, inhalation, nasal, vaginal or sublingual.
  • the peptides of the present invention may be formulated as, but not limited to, solutions, gels, ointments, creams, suspensions, or the like as are well-known in the art.
  • Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
  • the peptides of the present invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • the solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the peptides may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art.
  • the peptides can be readily formulated by combining the active peptides with pharmaceutically acceptable carriers known in the art.
  • Such carriers enable the peptides of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • solid dosage forms may be coated using standard techniques.
  • suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc. Additionally, flavoring agents, preservatives, coloring agents and the like may be added.
  • the peptides may take the form of tablets, lozenges, etc. formulated in conventional manner.
  • the peptides for use according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifiuoromethane, trichlorofiuoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifiuoromethane, trichlorofiuoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the peptides may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the peptides may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the peptides may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver peptides and peptide analogues of the invention.
  • Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the peptides may be delivered using a sustained-release system.
  • sustained-release materials have been established and are well known by those skilled in the art.
  • additional strategies for protein stabilization may be employed.
  • Pharmaceutically acceptable salts and derivatives according to the present invention are those salts and derivatives which substantially retain the biological activity of the free bases.
  • the pharmaceutically acceptable salt and derivatives includes salts and derivatives which can be prepared according to the person skilled in the art.
  • the peptides of the present invention will generally be used in an amount effective to achieve the intended purpose.
  • the peptides of the present invention or pharmaceutical compositions thereof are administered or applied in a therapeutically effective amount.
  • therapeutically effective amount is meant an amount effective to ameliorate or prevent the symptoms, or prolong the survival of, the patient being treated. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the dosage administered will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the peptides which are sufficient to maintain therapeutic effect.
  • Usual patient dosages for administration by injection range from about 0.1 to 50 mg/kg/day, preferably from about 0.5 to 10 mg/kg/day. Typically, 1 to 10 mg per kg per day given in doses either multiple times in a day (6 times) or a dose at every alternate day or sustained release form is effective to obtain desired results.
  • Dosage amount and interval may be adjusted individually to achieve plasma levels which are effective in ameliorating the pathological condition. Therapeutically effective serum levels may be achieved by administering multiple doses each day.
  • the effective local concentration of the peptides may not be related to plasma concentration.
  • One, having skill in the art, will be able to optimize therapeutically effective local dosages without undue experimentation.
  • the amount of peptide administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • the therapy may be repeated intermittently while symptoms detectable or even when they are not detectable.
  • the therapy may be provided alone or in combination with other drugs.
  • Example 1 a) Synthesis of peptide of sequence ID-6 Peptide of Sequence ID-6 was synthesized using solid phase peptide synthesis method on an automated or semi automated peptide synthesizer following Fmoc- chemistry. Wang resin was used for the synthesis . The substitution of the resin varied from 0.6 to 1.2 mmol/g. The side chain of tyrosine and serine was protected by tert-butyl group and the asparagine side chain was protected by trityl group. The loading of the first amino acid tyrosine to Wang resin was carried out using DIC/HOBt (3-5 eq) and DMAP (l-2eq) in DMF at room temp for about 5-8 hrs.
  • Reagent mixture 150 ml containing TFA:Phenol:TIS:DIT: Water in the ratio of 82.5:5.0:2.5:5.0:5.0 was used to cleave the peptide from the resin.
  • Resin loaded with peptide sequence ID-6 was kept in cleavage reagent under the ice cold environment for 15 min with constant stirring and then at room temperature for 2 hour with constant stirring. After the completion of reaction, mixture was filtered through sintered funnel and the peptide was precipitated by adding the cold di-ethyl-ether to the filtrate.
  • Precipitated peptide was filtered through the sintered funnel, dried, dissolved in water and finally freeze dried to obtain the crude peptide.
  • the crude yield of the peptide was 85-90%. Purification of peptide
  • the crude peptide was analyzed by analytical HPLC using acetonitrile and water as eluent.
  • Purification of crude BRC605-1 was done on (Shimadzu) HPLC LC-8A using C- 18 prep column (250 x 50 mm, lO ⁇ ) by isocratic elution in acetonitrile (0.1% TFA) water (0.1% TFA) mixture with a flow rate of 80-120 ml/min and a detection wavelength of 210 nm. Further the purified fraction was analyzed by analytical HPLC and desired fractions were pooled, lyophilized and characterized. The overall yield of the method was found be to be >70%.
  • Peptide sequencing Characterization by peptide sequencing of all batches of peptide sequence ID-6 has been done. The peptide sequence of each batch confers with the actual sequence.
  • Example - 2 Inhibition of TNF-alpha mediated cytotoxicity of L-929 cells by the peptide sequences:
  • the peptides of the present invention were analyzed for inhibition of TNF- alpha induced cytotoxicity employing murine fibroblast cell line, L929.
  • Addition of TNF-alpha to L929 cells (ATCC) induces cytotoxicity, which can be estimated by staining of viable cells with vital dyes like MTT (3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) or crystal violet followed by extraction of dyes with methanol. Absorbance of extracted dye can be measured at 595 nm (Hansen et al. 1989, Journal of Immunological Methods, 119: 203-210).
  • the assay was performed as follows: L929 cells (maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS) were seeded at a density of 2X10 5 cells/ml in a microtitre plates, and incubated with actinomycin D (ACT-D) at concentration of 1 ⁇ g/ml for 2h at 37°C and 5% CO 2 . TNF- ⁇ (100 pg/ml) preincubated with 75 ⁇ M of peptide solution at 37°C was added to L929 cells and incubated overnight at 37°C, 5% CO 2 .
  • ACT-D actinomycin D
  • Cyclic WSQYL (cy Trp-Ser-Gln-Tyr-Leu) peptide was used as positive control for estimating the inhibition of TNF related cytotoxicity.
  • TNF- ⁇ 100 pg/ml preincubated with positive control peptide solution (75 ⁇ M) at 37°C was added to L929 cells in a separate wells and incubated overnight at 37 0 C, 5% CO 2.
  • Peptides of Sequence IDs- 1 to 10 were analyzed for inhibition of TNF-alpha induced cytotoxicity.
  • the peptides with sequence ID-I, 2, 6 and 8 exhibited higher inhibition of TNF-alpha induced cytotoxicity when compared to the positive control.
  • the percent inhibition of cytotoxicity induced by TNF-alpha was 65 ⁇ 9.2%, 48 ⁇ 6%, 62 ⁇ 6.2%, 51 ⁇ 2.3% (Mean ⁇ SE% inhibition, calculated on the basis of experiments each run in duplicate), respectively for peptide with sequence ID of 1, 2, 6, and 8.
  • Linear peptides of Sequence ID-2 and Sequence ID-6 and cyclic peptides with Sequence ID - 9 and Sequence ID-IO were analyzed for comparing the ability to inhibit TNF-alpha induced cytotoxicity (using method as stated above). It was found that the linear peptides of Sequence ID-2 and ID-6 are more potent suppressors of TNF-alpha induced cytotoxicity than the cyclic forms of peptides Sequence ID- 9 and ID-IO. The cyclic forms of peptides of Sequence ID- 9 and ID-IO exhibited minimal degree of inhibition as shown in Figure 2.
  • Linear peptides of Sequence ID-2 and Sequence ID-6 were found to have inhibitory potential as high as that of cyclic forms of the positive control which is a known TNF-alpha inhibitory peptide.
  • Flow cytometry assay technique was used to investigate binding of peptides to TNF- ⁇ or TNF-Rl employing U937 cells (a TNF-receptor expressing human leukemia cell line). Binding of peptide to TNF- ⁇ prevents TNF- ⁇ from interacting with TNF-Rl which can be analyzed by flow cytometry. Similarly, direct binding of peptide with TNF-Rl reduces percent TNF-Rl positive cells which can be analyzed by flow cytometry.
  • TNF-alpha binds to its cognate receptor TNF-Rl on U937 cells (ATCC) leading to a reduction in percent cells positive for TNF-Rl.
  • TNF-alpha binding peptides bind to, TNF-alpha and prevent the interaction of TNF-alpha with TNF-RI.
  • the percent cells positive for TNF-Rl can be quantified by staining with fluorochrome conjugated anti-TNF-RI antibody.
  • Peptides of Sequence ID-2 and Sequence ID-6 were analyzed for inhibition of TNF-alpha binding to its receptor TNF-Rl on U937 cells. Inhibition of TNF- alpha binding to TNF-RI on U937 cells by peptides with sequence ID-2 or sequence ID-6 was estimated, using fluorescent activated cell sorter (FACS, FACSCALIBUR, Becton Dickinson, USA).
  • FACS fluorescent activated cell sorter
  • U937 cells (maintained in RPMI- 1640 medium (Sigma Aldrich, USA), supplemented with 10% FCS were suspended in PBS containing 0.5% BSA (Bovine Serum Albumin) and 0.05% NaN 3 (binding buffer) at a density of I xIO 5 cells per 100 ⁇ l of buffer.
  • BSA Bovine Serum Albumin
  • NaN 3 binding buffer
  • U937 (I x IO 5 ) cells were incubated in a separate tube (as a parallel experiment) with TNF-alpha (5ng) for 1 hr. at 4°C. The cells were then washed in binding buffer and 5 ⁇ l (1 mg/ml) of a human anti-mouse TNF receptor antibody was added (clone number HTR-9, Novus Biologicals), to the cells for 1 hr. at 4°C. These cells were then washed with binding buffer and stained with 10 ⁇ l (10 ⁇ g/ml) of fluorescein-conjugated goat anti-mouse IgG secondary antibody (GIBCO BRL, Gaithersburg, Md.) for 30 min. at 4° C in dark.
  • GIBCO BRL fluorescein-conjugated goat anti-mouse IgG secondary antibody
  • the cells were analyzed using FACS Calibur flow cytometer (Becton Dickinson). The gates were set on the live cell population, and the degree of inhibition of TNF- ⁇ /cell binding by peptides was calculated on the basis of percent cells positive for TNF-RI expression.
  • U937 cells were used to quantify the binding of peptides to TNF-Rl.
  • TNF- alpha upon addition to U937 cells binds to its cognate receptor TNF-Rl on U937 cells leading to a reduction in percent cells positive for TNF-Rl.
  • TNF- alpha inhibiting peptides according to present invention bind to TNF-Rl and reduce the TNF-Rl positive cells after incubation of U937 cells with said peptides.
  • Peptide of Sequence ID - 6 was analyzed for binding of peptide to TNF-Rl on U937 cells using flow cytometry.
  • U937 cells were incubated with the peptide of Sequence ID-6 to demonstrate direct binding of peptide Sequence ID- 6 to TNF-Rl receptor.
  • peptide of sequence ID-6 250 ⁇ M
  • TNF-alpha IOng
  • U937 cells were washed twice and stained with 5 ⁇ l (1 mg/ml) of a human anti-mouse TNF receptor antibody (clone number HTR-9, Novus Biologicals) for Ih at 4°C.
  • Example - 5(a) Development of mouse model for arthritis Male C57BL/6 mice obtained from animal house at Lalru, Panacea Biotec were used to develop a murine model of rheumatoid arthritis. Mice were intradermally immunized with 150 ⁇ g of chicken type-II collagen (Sigma) emulsified in complete Freunds adjuvant (CFA) (Sigma). On day 17 after primary immunization, a booster immunization with lOO ⁇ g of chick type II collagen in incomplete Freunds adjuvant was administered to animals (Ethan M Shevach, Curr. Prot. Immunol.
  • CFA complete Freunds adjuvant
  • Example - 5(c) Optimization of dose and schedule in murine model Determination of optimum dose and schedule of peptide with Sequence ID-6 was performed in a murine model of collagen induced arthritis (as prepared above). Arthritic mice were randomized according to paw thickness and divided into separate groups of 4- 5 animals for intravenous administration of peptide sequence ID-6. Table - 3 shows the dose and schedule of administration for different groups:
  • Example - 5(d) Comparative efficacy of peptide sequence ID-6, ID-2 and Etanercept in murine model:
  • Efficacy of peptide with sequence ID-6 and sequence ID-2 was compared with Etanercept (Marketed and approved TNF-alpha inhibiting agent with the brand name "Enbrel”) using a murine model of collagen induced arthritis (As prepared and described above).
  • Peptides of Sequence ID-6, Sequence ID-2 and Etanercept were intravenously administered to the arthritic mice at a dose of 5mg/kg three times in first week followed by once every week for three weeks.
  • Example 5 (e) - Comparative study for determining the IgGl/IgG2a ratios after therapy in animals treated with Peptides of Sequence ID-2, Sequence ID- 6 and Etanercept. Development of disease in collagen induced arthritis is accompanied by an increase in ThI or proinflammatory response. IgGl/IgG2a levels were measured to determine that whether treatment with the peptides of the present invention and Etanercept improved clinical disease in murine model by decreasing ThI response. Lower IgGl/IgG2a ratio would indicate down regulation of ThI or proinflammatory response.
  • Peptides of Sequence ID-2 and Sequence ID-6, Etanercept, PBS were intravenously administered to the arthritic mice at a dose of 5mg/kg three times in first week followed by once every week for three weeks. It was found that administration of peptides with sequence ID - 6 and Etanercept resulted in lower ratio of IgGl/IgG2a after therapy as compared to untreated (PBS treated animals are considered as untreated animals) arthritic animals ( Figure 8b). Untreated arthritic animals (PBS treated animals are considered as untreated animals) exhibited higher IgGl/IgG2a ratio due to ongoing inflammation.
  • Adjuvant arthritis in rats mimics features of inflammatory arthritis in humans (Pearson et al, 1956, Proc. Soc. Exp. Biol. Med. 112:95-10). AA was induced in male Wistar rats by intradermal immunization with 150 ⁇ g of complete freunds adjuvant followed by a booster immunization at day 7 with incomplete freunds adjuvant. Arthritis was evaluated in animals by clinical scoring and measurement of paw and joint thickness using digital vernier calipers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PCT/IN2009/000626 2008-11-20 2009-11-05 Tumor necrosis factor alpha inhibiting peptides and uses thereof WO2010058419A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2011537012A JP2012509312A (ja) 2008-11-20 2009-11-05 腫瘍壊死因子α阻害ペプチドおよびその使用方法
EP09827268A EP2362880A1 (en) 2008-11-20 2009-11-05 Tumor necrosis factor alpha inhibiting peptides and uses thereof
CA2744365A CA2744365A1 (en) 2008-11-20 2009-11-05 Tumor necrosis factor alpha inhibiting peptides and uses thereof
AU2009318779A AU2009318779A1 (en) 2008-11-20 2009-11-05 Tumor Necrosis Factor alpha inhibiting peptides and uses thereof
CN2009801545421A CN102282163A (zh) 2008-11-20 2009-11-05 肿瘤坏死因子-α抑制肽及其应用
SG2011036068A SG171348A1 (en) 2008-11-20 2009-11-05 Tumor necrosis factor alpha inhibiting peptides and uses thereof
MA33940A MA33084B1 (fr) 2008-11-20 2009-11-05 Peptides inhibant le facteur de nécrose tumorale alpha et leurs utilisations
MX2011005363A MX2011005363A (es) 2008-11-20 2009-11-05 Peptidos para inhibicion del factor alfa de necrosis tumoral y usos de los mismos.
US13/130,267 US20120010158A1 (en) 2008-11-20 2009-11-05 Tumor necrosis factor inhibiting peptides and uses thereof
RU2011151260/02A RU2011151260A (ru) 2008-11-20 2009-11-05 Пептиды, ингибирующие фактор некроза опухолей альфа, и их применения
IL213026A IL213026A0 (en) 2008-11-20 2011-05-19 TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2622DE2008 2008-11-20
IN2622/DEL/2008 2008-11-20

Publications (2)

Publication Number Publication Date
WO2010058419A1 true WO2010058419A1 (en) 2010-05-27
WO2010058419A4 WO2010058419A4 (en) 2010-07-29

Family

ID=42197885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000626 WO2010058419A1 (en) 2008-11-20 2009-11-05 Tumor necrosis factor alpha inhibiting peptides and uses thereof

Country Status (16)

Country Link
US (1) US20120010158A1 (es)
EP (1) EP2362880A1 (es)
JP (1) JP2012509312A (es)
KR (1) KR20110093899A (es)
CN (1) CN102282163A (es)
AR (1) AR074388A1 (es)
AU (1) AU2009318779A1 (es)
CA (1) CA2744365A1 (es)
CO (1) CO6362019A2 (es)
IL (1) IL213026A0 (es)
MA (1) MA33084B1 (es)
MX (1) MX2011005363A (es)
PE (1) PE20110708A1 (es)
RU (1) RU2011151260A (es)
SG (1) SG171348A1 (es)
WO (1) WO2010058419A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10705094B2 (en) 2015-06-18 2020-07-07 UCB Biopharma SRL TNF receptor signaling modulator assay
US11174311B2 (en) 2016-12-21 2021-11-16 UCB Biopharma SRL Antibody against trimeric TNFα complex

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004752A (ko) 2015-05-26 2018-01-12 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用
CN107383174B (zh) * 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途
CN114641484B (zh) * 2019-11-05 2024-08-09 国立大学法人京都大学 肽、组合物及治疗、预防或改善心境障碍的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026744A1 (en) * 1994-04-01 1995-10-12 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026744A1 (en) * 1994-04-01 1995-10-12 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 14 November 2006 (2006-11-14), Database accession no. Z97362.1. *
DATABASE EMBL 14 November 2006 (2006-11-14), Database accession no. Z97363.1. *
DATABASE EMBL 15 November 2006 (2006-11-15), Database accession no. AJ542538.1. *
DATABASE EMBL 16 October 2006 (2006-10-16), Database accession no. AJ305217.1. *
DATABASE GENBANK Database accession no. CAB10588 *
DATABASE GENBANK Database accession no. CAB10589 *
DATABASE GENBANK Database accession no. CAC43227 *
DATABASE GENBANK Database accession no. CAD66058 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10705094B2 (en) 2015-06-18 2020-07-07 UCB Biopharma SRL TNF receptor signaling modulator assay
US10775385B2 (en) 2015-06-18 2020-09-15 UCB Biopharma SRL Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
US10883996B2 (en) 2015-06-18 2021-01-05 UCB Biopharma SRL Methods of identifying signaling modulators of the trimeric TNFa
US10969393B2 (en) 2015-06-18 2021-04-06 UCB Biopharma SRL Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them
US11022614B2 (en) 2015-06-18 2021-06-01 UCB Biopharma SRL Antibodies binding to trimeric TNF alpha epitopes
US11448655B2 (en) 2015-06-18 2022-09-20 UCB Biopharma SRL Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors
US11674967B2 (en) 2015-06-18 2023-06-13 UCB Biopharma SRL Method of identifying potential inhibitors of APO TNFα trimers
US12055549B2 (en) 2015-06-18 2024-08-06 UCB Biopharma SRL Methods of use of anti-TNFα antibodies
US11174311B2 (en) 2016-12-21 2021-11-16 UCB Biopharma SRL Antibody against trimeric TNFα complex

Also Published As

Publication number Publication date
EP2362880A1 (en) 2011-09-07
CN102282163A (zh) 2011-12-14
MX2011005363A (es) 2011-08-12
US20120010158A1 (en) 2012-01-12
AR074388A1 (es) 2011-01-12
CO6362019A2 (es) 2012-01-20
WO2010058419A4 (en) 2010-07-29
CA2744365A1 (en) 2010-05-27
KR20110093899A (ko) 2011-08-18
JP2012509312A (ja) 2012-04-19
RU2011151260A (ru) 2013-06-20
MA33084B1 (fr) 2012-03-01
AU2009318779A1 (en) 2011-07-07
PE20110708A1 (es) 2011-10-23
IL213026A0 (en) 2011-07-31
SG171348A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
EP3454880B1 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
US8017585B2 (en) CXCR4 antagonist and use thereof
JP4006021B2 (ja) ケモカインの生物学的活性の強化法
JP6474786B2 (ja) 虚血性損傷の治療及び予防用の組成物
US20120010158A1 (en) Tumor necrosis factor inhibiting peptides and uses thereof
HUT73494A (en) Analogs of peptide yy and uses thereof
JP2008531608A (ja) Ｙｋｌ−４０モノクローナル抗体
SK55193A3 (en) Bombesin antagonists
JP5652987B2 (ja) ヒトＩｇＧＦｃレセプターＩＩｂ（ＦｃγＲＩＩｂ）に結合する物質
Döring et al. Identification and characterization of a TNFα antagonist derived from a monoclonal antibody
KR20140135766A (ko) 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법
US8003610B2 (en) Bradykinin B2 receptor antagonist peptide from amphibian skin
JP2023534949A (ja) グルカゴン誘導体又はその結合体の肝臓疾患に対する治療的用途
US5786335A (en) Sulfhydryl containing peptides for treating vascular disease
WO1999025731A1 (fr) Peptides cycliques et leur utilisation medicinale
WO1993000108A1 (en) Novel inhibitors of platelet aggregation
US7371724B2 (en) KAPREKY peptidomimetics and analogues thereof
Siemion et al. The immunosuppressive mini‐domain of human lactoferrin
JP2967956B2 (ja) ペプチドまたはその塩
RU2442791C1 (ru) Способ получения бусерелина и промежуточные соединения для его получения
O Moustafa Peptide Chemistry's Contribution to the Treatment of the Majority of Serious Illnesses: Peptide Antitumors.
JP2004107333A (ja) Ｃｘｃｒ４拮抗薬およびその用途
WO2024168055A1 (en) Tnf-alpha binding agents and methods of using the same
WO2024094685A1 (en) Ccr2 inhibitors and methods of use
Shaw et al. Bradykinin B2 receptor antagonist peptide from amphibian skin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980154542.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827268

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2011537012

Country of ref document: JP

Ref document number: 2744365

Country of ref document: CA

Ref document number: 213026

Country of ref document: IL

Ref document number: 13130267

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011001185

Country of ref document: CL

Ref document number: 001061-2011

Country of ref document: PE

Ref document number: MX/A/2011/005363

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 593165

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009827268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009318779

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20117013710

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11076056

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201107637

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2009318779

Country of ref document: AU

Date of ref document: 20091105

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011151260

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0921925

Country of ref document: BR

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0921925

Country of ref document: BR

Free format text: PEDIDO RETIRADO, UMA VEZ QUE NAO HOUVE MANIFESTACAO DO REQUERENTE FRENTE A PUBLICACAO DO ARQUIVAMENTO DA PETICAO (11.6.1) NA RPI 2380 DE 16/08/2016